Ikarian Capital’s BeOne Medicines Ltd ONC Stock Holding History

Ikarian Capital’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-29,800	Closed	-$5.5M	–	227
2024 Q4	$5.5M	Hold	29,800	–	–	0.75%	37
2024 Q3	$6.69M	Buy	+29,800	New	+$5.36M	0.93%	28
2021 Q2	–	Sell	-10,500	Closed	-$3.65M	–	298
2021 Q1	$3.65M	Buy	+10,500	New	+$3.48M	0.12%	152

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Ikarian Capital's ONC Position: Q4 2024 in Review

Ikarian Capital sold out of BeOne Medicines Ltd (ONC) in Q4 2024, closing a stake of 88,167 shares — an estimated $18M sold.

Ikarian Capital first reported a position in ONC in Q3 2024 and held it in 1 quarter. The position peaked at $1.64M in Q3 2024. 228 funds tracked by Wall St. Rank hold ONC as of Q4 2024.

Ikarian Capital reported no remaining BeOne Medicines Ltd position as of Q4 2024 after selling out during the quarter.
Ikarian Capital sold 88,167 BeOne Medicines Ltd shares in Q4 2024, an estimated $18M.
Ikarian Capital first reported a position in BeOne Medicines Ltd in Q3 2024 and held it in 1 quarter.
Ikarian Capital's BeOne Medicines Ltd position peaked at $1.64M in Q3 2024.
228 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q4 2024.

Based on Ikarian Capital's 13F filing for Q4 2024, filed 14 Feb 2025.